Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Summary Background The uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis C virus (HCV) NS5B polymerase. We assessed the safety and...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TRIPLE THERAPY | BOCEPREVIR | TELAPREVIR | ADVERSE EVENTS | LIFE | Uridine Monophosphate - administration & dosage | Puerto Rico | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - analogs & derivatives | Female | Drug Therapy, Combination | Hepatitis C, Chronic - genetics | Sofosbuvir | Complications and side effects | Peginterferon alfa-2a | Dosage and administration | Research | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Liver cirrhosis | Drug dosages
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TRIPLE THERAPY | BOCEPREVIR | TELAPREVIR | ADVERSE EVENTS | LIFE | Uridine Monophosphate - administration & dosage | Puerto Rico | United States | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - administration & dosage | Uridine Monophosphate - analogs & derivatives | Female | Drug Therapy, Combination | Hepatitis C, Chronic - genetics | Sofosbuvir | Complications and side effects | Peginterferon alfa-2a | Dosage and administration | Research | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Genotype & phenotype | Infections | Liver cirrhosis | Drug dosages
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9751, pp. 1467 - 1475
Summary Background Present interferon-based standard of care treatment for chronic hepatitis C virus (HCV) infection is limited by both efficacy and...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | VIRUS | TELAPREVIR | INDUCIBLE PROTEIN-10 | LIVER FIBROSIS | IN-VIVO | RESISTANCE | DYNAMICS | RIBAVIRIN | PEGINTERFERON | ITMN-191 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Recombinant Proteins | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Lactams - adverse effects | Double-Blind Method | Administration, Oral | Deoxycytidine - administration & dosage | Lactams - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Clinical trials | Dosage and administration | Protease inhibitors | Hepatitis C | Drug therapy | Studies | Stock options | Meetings | Mortality | RNA polymerase | Tropical diseases | Antiviral activity
Internal Medicine | MEDICINE, GENERAL & INTERNAL | VIRUS | TELAPREVIR | INDUCIBLE PROTEIN-10 | LIVER FIBROSIS | IN-VIVO | RESISTANCE | DYNAMICS | RIBAVIRIN | PEGINTERFERON | ITMN-191 | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Recombinant Proteins | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Lactams - adverse effects | Double-Blind Method | Administration, Oral | Deoxycytidine - administration & dosage | Lactams - administration & dosage | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Clinical trials | Dosage and administration | Protease inhibitors | Hepatitis C | Drug therapy | Studies | Stock options | Meetings | Mortality | RNA polymerase | Tropical diseases | Antiviral activity
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug...
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 1, pp. 34 - 44
In this small, preliminary study of sofosbuvir, a nucleotide inhibitor of HCV polymerase, treatment with sofosbuvir and ribavirin, without peginterferon, was...
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
GENOTYPE 1 | PSI-7977 | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | THERAPY | REPLICATION | RESISTANCE | REPLICON RNA-SYNTHESIS | COMBINATION | TREATMENT-NAIVE PATIENTS | PROTEASE | Recombinant Proteins - therapeutic use | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Viral Load | Adult | Female | RNA, Viral - metabolism | Uridine Monophosphate - adverse effects | Drug Therapy, Combination | Uridine Monophosphate - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Hemoglobins - metabolism | Genotype | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Interferon-alpha - adverse effects | Viral Nonstructural Proteins - antagonists & inhibitors | Sofosbuvir | Drugs | Dose-response relationship (Biochemistry) | Antiviral agents | Usage | Patient outcomes | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Hepatitis | Interferon | Infections | Index Medicus | Abridged Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/1998, Volume 95, Issue 15, pp. 8869 - 8873
The presence of latently infected, resting CD4 T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are...
T lymphocytes | Highly active antiretroviral therapy | HIV | Viremia | Viruses | Disease reservoirs | Infections | Symptoms | HIV 1 | Blood plasma | Primary infection | HAART therapy | Latency | RESPONSES | PLASMA | MULTIDISCIPLINARY SCIENCES | latency | IN-VIVO | primary infection | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | Physiological aspects | Research | T cells | HIV infection
T lymphocytes | Highly active antiretroviral therapy | HIV | Viremia | Viruses | Disease reservoirs | Infections | Symptoms | HIV 1 | Blood plasma | Primary infection | HAART therapy | Latency | RESPONSES | PLASMA | MULTIDISCIPLINARY SCIENCES | latency | IN-VIVO | primary infection | AIDS | HUMAN-IMMUNODEFICIENCY-VIRUS | Physiological aspects | Research | T cells | HIV infection
Journal Article
Nature Medicine, ISSN 1078-8956, 06/1999, Volume 5, Issue 6, pp. 651 - 655
The size of the pool of resting CD4(+) T cells containing replication-competent HIV in the blood of patients receiving intermittent interleukin (IL)-2 plus...
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | CONTROLLED TRIAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIRETROVIRAL THERAPY | HUMAN-IMMUNODEFICIENCY-VIRUS | COMBINATION | CELL BIOLOGY | INDIVIDUALS | VIREMIA | CANCER-PATIENTS | REPLICATION | HIV ERADICATION | Virus Replication - drug effects | HIV-1 - pathogenicity | Cross-Sectional Studies | HIV-1 - drug effects | Humans | Interleukin-2 - therapeutic use | RNA, Viral - blood | Lymph Nodes - virology | HIV Protease Inhibitors - therapeutic use | Interleukin-2 - pharmacology | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Lymphocyte Count - drug effects | CD4-Positive T-Lymphocytes - virology | CD4-Positive T-Lymphocytes - drug effects | Highly active antiretroviral therapy | Interleukin-2 | Physiological aspects | Drug therapy | HIV (Viruses) | HIV infection | Health aspects
MEDICINE, RESEARCH & EXPERIMENTAL | ACTIVATION | CONTROLLED TRIAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANTIRETROVIRAL THERAPY | HUMAN-IMMUNODEFICIENCY-VIRUS | COMBINATION | CELL BIOLOGY | INDIVIDUALS | VIREMIA | CANCER-PATIENTS | REPLICATION | HIV ERADICATION | Virus Replication - drug effects | HIV-1 - pathogenicity | Cross-Sectional Studies | HIV-1 - drug effects | Humans | Interleukin-2 - therapeutic use | RNA, Viral - blood | Lymph Nodes - virology | HIV Protease Inhibitors - therapeutic use | Interleukin-2 - pharmacology | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Lymphocyte Count - drug effects | CD4-Positive T-Lymphocytes - virology | CD4-Positive T-Lymphocytes - drug effects | Highly active antiretroviral therapy | Interleukin-2 | Physiological aspects | Drug therapy | HIV (Viruses) | HIV infection | Health aspects
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2006, Volume 46, Issue 5, pp. 577 - 587
Aplaviroc is a novel CCR5 antagonist, a class of compounds under investigation as viral entry inhibitors for the treatment of human immunodeficiency virus...
drug interactions | biomarker | CCR5 | Cytochrome P450 | Biomarker | Drug interactions | CHINESE | cytochrome P450 | COMBINED PHENOTYPIC ASSESSMENT | CCR5 ANTAGONIST | S-MEPHENYTOIN | XANTHINE-OXIDASE | PHARMACOKINETICS | CYP2D6 GENE | PHARMACOLOGY & PHARMACY | POLYMERASE CHAIN-REACTION | METABOLIZING-ENZYMES | DISEASE PROGRESSION | Benzoates - adverse effects | Humans | Middle Aged | Omeprazole - blood | Aryl Hydrocarbon Hydroxylases - genetics | Male | Spiro Compounds - adverse effects | Caffeine - pharmacokinetics | Drug Interactions | Adult | Female | Dextromethorphan - pharmacokinetics | Anti-HIV Agents - blood | Piperazines - pharmacokinetics | Piperazines - blood | CCR5 Receptor Antagonists | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Anti-HIV Agents - adverse effects | Caffeine - blood | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Piperazines - adverse effects | Spiro Compounds - pharmacokinetics | Aryl Hydrocarbon Hydroxylases - metabolism | Warfarin - pharmacokinetics | Benzoates - blood | Midazolam - blood | Anti-HIV Agents - pharmacokinetics | Dextromethorphan - urine | Spiro Compounds - blood | Warfarin - blood | Benzoates - pharmacokinetics | Antiviral agents | Dosage and administration | Research | Drug therapy | HIV infection | Anti-HIV agents
drug interactions | biomarker | CCR5 | Cytochrome P450 | Biomarker | Drug interactions | CHINESE | cytochrome P450 | COMBINED PHENOTYPIC ASSESSMENT | CCR5 ANTAGONIST | S-MEPHENYTOIN | XANTHINE-OXIDASE | PHARMACOKINETICS | CYP2D6 GENE | PHARMACOLOGY & PHARMACY | POLYMERASE CHAIN-REACTION | METABOLIZING-ENZYMES | DISEASE PROGRESSION | Benzoates - adverse effects | Humans | Middle Aged | Omeprazole - blood | Aryl Hydrocarbon Hydroxylases - genetics | Male | Spiro Compounds - adverse effects | Caffeine - pharmacokinetics | Drug Interactions | Adult | Female | Dextromethorphan - pharmacokinetics | Anti-HIV Agents - blood | Piperazines - pharmacokinetics | Piperazines - blood | CCR5 Receptor Antagonists | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Anti-HIV Agents - adverse effects | Caffeine - blood | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Piperazines - adverse effects | Spiro Compounds - pharmacokinetics | Aryl Hydrocarbon Hydroxylases - metabolism | Warfarin - pharmacokinetics | Benzoates - blood | Midazolam - blood | Anti-HIV Agents - pharmacokinetics | Dextromethorphan - urine | Spiro Compounds - blood | Warfarin - blood | Benzoates - pharmacokinetics | Antiviral agents | Dosage and administration | Research | Drug therapy | HIV infection | Anti-HIV agents
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2006, Volume 62, Issue 3, pp. 336 - 344
Aims This study assessed the effects of the CYP3A inhibitors lopinavir/ritonavir (LPV/r) on the steady‐state pharmacokinetics (PK) of aplaviroc (APL), a CYP3A4...
lopinavir | CCR5 | aplaviroc | drug interaction | ritonavir | Drug interaction | Aplaviroc | Ritonavir | Lopinavir | HIV | MECHANISM | SAFETY | SAQUINAVIR | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITORS | Humans | Middle Aged | Pyrimidinones - therapeutic use | Rats | Male | Spiro Compounds - pharmacokinetics | Animals | Drug Interactions | Adolescent | Ritonavir - therapeutic use | Adult | Female | HIV Infections - drug therapy | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Mice | Piperazines - pharmacokinetics | Drug Combinations | Benzoates - pharmacokinetics | CCR5 Receptor Antagonists | Antiviral agents | Analysis | Anti-HIV agents
lopinavir | CCR5 | aplaviroc | drug interaction | ritonavir | Drug interaction | Aplaviroc | Ritonavir | Lopinavir | HIV | MECHANISM | SAFETY | SAQUINAVIR | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITORS | Humans | Middle Aged | Pyrimidinones - therapeutic use | Rats | Male | Spiro Compounds - pharmacokinetics | Animals | Drug Interactions | Adolescent | Ritonavir - therapeutic use | Adult | Female | HIV Infections - drug therapy | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Mice | Piperazines - pharmacokinetics | Drug Combinations | Benzoates - pharmacokinetics | CCR5 Receptor Antagonists | Antiviral agents | Analysis | Anti-HIV agents
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 07/1998, Volume 95, Issue 15, pp. 8869 - 8873
The presence of latently infected, resting CD4 + T cells carrying replication-competent HIV-1 has been demonstrated in chronically infected individuals who are...
Lamivudine - administration & dosage | Indinavir - administration & dosage | Virus Latency | Humans | HIV Protease Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Virus Integration | HIV Protease Inhibitors - therapeutic use | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | HIV Infections - immunology | HIV-1 - physiology | Virus Replication | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Zidovudine - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | CD4-Positive T-Lymphocytes - virology | DNA, Viral - genetics | Drug Therapy, Combination | Indinavir - therapeutic use | Biological Sciences | primary infection | HAART therapy | latency
Lamivudine - administration & dosage | Indinavir - administration & dosage | Virus Latency | Humans | HIV Protease Inhibitors - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Virus Integration | HIV Protease Inhibitors - therapeutic use | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | HIV Infections - immunology | HIV-1 - physiology | Virus Replication | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Anti-HIV Agents - therapeutic use | HIV Infections - drug therapy | Zidovudine - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | CD4-Positive T-Lymphocytes - virology | DNA, Viral - genetics | Drug Therapy, Combination | Indinavir - therapeutic use | Biological Sciences | primary infection | HAART therapy | latency
Journal Article
Consultant, ISSN 0010-7069, 1997, Volume 37, Issue 5, pp. 1243 - 1244
Journal Article
No results were found for your search.
Cannot display more than 1000 results, please narrow the terms of your search.